Login / Signup

The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios.

Ourania S KotsiouNikolaos D KarakousisDimitrios PapagiannisElena MatsiatsiouDimitra AvgeriEvangelos C FradelosDimitra I SiachpazidouGarifallia PerlepeAngeliki MiziouAthanasios KyritsisEudoxia GogouGeorgios D VavougiosGeorge KalantzisKonstantinos I Gourgoulianis
Published in: Journal of personalized medicine (2022)
Background: Both SARS-CoV-2 infection and/or vaccination result in the production of SARS-CoV-2 antibodies. We aimed to compare the antibody titers against SARS-CoV-2 in different scenarios for antibody production. Methods: A surveillance program was conducted in the municipality of Deskati in January 2022. Antibody titers were obtained from 145 participants while parallel recording their infection and/or vaccination history. The SARS-CoV-2 IgG II Quant method (Architect, Abbott, IL, USA) was used for antibody testing. Results: Advanced age (>56 years old) was associated with higher antibody titers. No significant differences were detected in antibody titers among genders, BMI, smoking status, comorbidities, vaccine brands, and months after the last dose. Hospitalization length and re-infection were predictors of antibody titers. The individuals who were fully or partially vaccinated and were also double infected had the highest antibody levels (25,017 ± 1500 AU/mL), followed by people who were fully vaccinated (20,647 ± 500 AU/mL) or/partially (15,808 ± 1800 AU/mL) vaccinated and were infected once. People who were only vaccinated had lower levels of antibodies (9946 ± 300 AU/mL), while the lowest levels among all groups were found in individuals who had only been infected (1124 ± 200 AU/mL). Conclusions: Every hit (infection or vaccination) gives an additional boost to immunization status.
Keyphrases
  • sars cov
  • climate change
  • body mass index
  • gold nanoparticles
  • quantum dots